CliffBio
small molecule

OZEMPIC

SEMAGLUTIDE

Loss of exclusivityFebruary 2039latest FDA-listed patent expiry
CompanyNOVO NORDISK INC

Drug detail

Brand nameOZEMPIC
Active ingredientSEMAGLUTIDE
Strength1.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2024
Marketing statusRX

Listed patents

PatentExpiresType
12396953February 2039product
11833248February 2039product
12514822May 2034use U-2628
12239739May 2034substance, product
10278923May 2034substance, product
11033499June 2033product
11382957December 2031substance, product
8129343December 2031substance, product
8536122March 2026substance, product

Regulatory exclusivity

CodeExpires
I-976October 2028

More from NOVO NORDISK INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OZEMPIC patent cliff — loss of exclusivity February 2039 | CliffBio